ONCOTYPE DX.

Individuals diagnosed with early-stage, hormone receptor-positive (HR+), HER2-negative breast cancer who need guidance on treatment planning. Patients and oncologists seeking to understand the risk of cancer recurrence and the potential benefit of chemotherapy. Those looking for a personalized, genomics-based approach to breast cancer treatment decisions, helping avoid unnecessary therapies where appropriate.